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ABSTRACT
Introduction: A motor vehicle collision (MVC) is one
of the most common life-threatening events
experienced by individuals living in the USA. While
most individuals recover following MVC, a significant
proportion of individuals develop adverse post-
traumatic sequelae such as post-traumatic stress
disorder or persistent musculoskeletal pain. Adverse
post-traumatic sequelae are common, morbid and
costly public health problems in the USA and other
industrialised countries. The pathogenesis of these
disorders following MVC remains poorly understood.
In the USA, available data suggest that African-
Americans experience an increased burden of adverse
post-traumatic sequelae after MVC compared to
European Americans, but to date no studies
examining the pathogenesis of these disorders among
African-Americans experiencing MVC have been
performed.
Methods and analysis: The African-American
CRASH (AA CRASH) study is an NIH-funded,
multicentre, prospective study that enrols African-
Americans (n=900) who present to the emergency
department (ED) within 24 hours of MVC. Participants
are enrolled at 13 ED sites in the USA. Individuals who
are admitted to the hospital or who report a fracture or
tissue injury are excluded. Participants complete a
detailed ED interview that includes an assessment of
crash history, current post-traumatic symptoms and
health status prior to the MVC. Blood samples are also
collected in the ED using PAXgene DNA and PAXgene
RNA tubes. Serial mixed-mode assessments 6 weeks,
6 months and 1 year after MVC include an assessment
of adverse sequelae, general health status and health
service utilisation. The results from this study will
provide insights into the incidence and pathogenesis of
persistent pain and other post-traumatic sequelae in
African-Americans experiencing MVC.
Ethics and dissemination: AA CRASH has ethics
approval in the USA, and the results will be published
in a peer-reviewed journal.
BACKGROUND
More than 50 million motor vehicle colli-
sions (MVC) occur worldwide each year,1
and more than 10 million of these MVCs
occur each year in the USA.2 More than 4
million of these individuals present to US
emergency departments (EDs) after the
MVC for evaluation,2 and the overwhelming
majority (>90%) of these individuals are dis-
charged to home without fracture or other
Strengths and limitations of this study
▪ African-American CRASH enrols African-
Americans, an understudied but highly burdened
population, and will determine incidence and risk
factors of adverse post-traumatic sequelae fol-
lowing motor vehicle collision trauma in this
population.
▪ Biological samples including blood tubes will be
collected and analysed for pathogenic mediators
of adverse post-traumatic sequelae.
▪ Collecting data from 900 participants across 13
emergency departments and at multiple time
points has inherent challenges, including poten-
tial loss to follow-up and participant
heterogeneity.
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identifiable injury.3 Although most of these discharged
individuals recover, a substantial proportion develops
persistent musculoskeletal pain and/or persistent psycho-
logical sequelae such as post-traumatic stress disorder
(PTSD).4–6 The development of these adverse post-
traumatic sequelae after MVC constitutes a common,
morbid and costly public health problem in industria-
lised countries.7–9 The pathogenesis of adverse sequelae
after MVC remains poorly understood.
In the USA, more than 1 million African-Americans
present to the ED for care after minor MVC each year,10
but to date no prospective studies of chronic musculo-
skeletal pain development in African-Americans experi-
encing MVC have been performed. A study evaluating
the incidence and pathogenesis of persistent musculo-
skeletal pain and other adverse post-traumatic sequelae
in African-Americans experiencing MVC is valuable for
several reasons. First, African-Americans experience an
increased burden of MVCs compared to European
Americans.10 Second, several lines of evidence suggest
that African-Americans experience a greater burden of
chronic pain development after MVC. For example, in
other clinical conditions, African-Americans have been
consistently shown to experience a greater burden of
chronic pain than European Americans,11–20 and in
laboratory settings, African-Americans have been found
to have increased sensitivity to experimental pain.20–26
Some of this increased vulnerability is likely due to
greater socioeconomic disadvantage;27–29 however, data
from other settings demonstrate that worse health out-
comes in African-Americans are not accounted for by
socioeconomic differences alone.27 30–32 Third, studies
of African-Americans can most effectively evaluate the
influence of factors that may be particularly relevant
within this ethnic group, such as discrimination.
Unfortunately, discrimination is a fundamental aspect of
the social structure of the USA and a daily reality for
African-Americans.33–36 Discrimination has been asso-
ciated with worse mental health outcomes37 (eg, depres-
sion38–43) and worse physical health outcomes,37 44 45
and may influence chronic pain and neuropsychologi-
cal outcomes after MVC. Finally and more generally,
evaluating the pathogenesis of a disorder among a high-
risk population using molecular and epidemiological
methods is a valuable approach to gaining new insights
into disease pathogenesis.46–49 In this article, we
describe the methods of a large-scale, NIH-funded, lon-
gitudinal study evaluating the incidence and pathogen-
esis of chronic pain and neuropsychological outcomes
among African-Americans experiencing MVC.
METHODS/DESIGN
Study sites
The African-American (AA) CRASH study is a prospect-
ive, multicentre, observational cohort study of
African-Americans who have experienced MVC. Study
participants are enrolled at research network ED sites
and complete an initial interview assessment in the ED.
Mixed-mode study participant follow-up assessments are
performed at 6 weeks, 6 months and 1 year via phone,
web or mail. The study research network (‘TRYUMPH
Research Network’) includes UAB Hospital
(Birmingham, Alabama, USA), UF Health Jacksonville
( Jacksonville, Florida, USA), Henry Ford Hospital
(Detroit, Michigan, USA), Sinai-Grace Hospital (Detroit,
Michigan, USA), Albert Einstein Medical Center
(Philadelphia, Pennsylvania, USA), Detroit Receiving
Hospital (Detroit, Michigan, USA), St. Joseph Mercy Ann
Arbor Hospital (Ypsilanti, Michigan, USA), Medstar
Washington Hospital Center (Washington DC, USA),
Boston Medical Center (Boston, Massachusetts, USA),
St. Joseph’s Regional Medical Center (Paterson, New
Jersey, USA), Spectrum Health Butterworth Hospital
(Grand Rapids, Michigan, USA), William Beaumont
Hospital (Royal Oak, Michigan, USA) and Baystate
Medical Center (Springfield, Massachusetts, USA). The
study was approved by the institutional review boards of
all participating hospitals. The data coordinating centre
for the study is located at the University of North
Carolina, Chapel Hill, North Carolina, USA, and the
study’s IRB approval number is 11-1742.
Inclusion criteria
Patients aged 18–65 years who present to the ED within
24 hours after MVC and who are unlikely to be admitted
to the hospital are screened for eligibility. Patients with
injuries likely to require hospitalisation are excluded, as
are patients with fractures (other than small bone frac-
tures), major lacerations (lacerations more than 20 cm
in length or more than 4 lacerations requiring sutures),
intracranial injury or spinal injury (defined as vertebral
fracture or dislocation, or new neurologic deficit).
Patients admitted to the hospital overnight are also
excluded, as are prisoners, pregnant patients, patients
not alert and oriented, patients whose phone was
disconnected in the past year and patients unable to
read and understand English. Individuals who are
certain at the time of ED presentation that they will liti-
gate are also excluded, to help ensure that a proportion
of individuals not engaged in litigation are enrolled.
Patients are also excluded if they take opioids above a
dose of 20 mg of oxycodone daily or equivalent. In add-
ition, since the goal of the study is to evaluate an
African-American sample, only non-Hispanic African-
American patients, based on self-report, are evaluated
for eligibility. After assessment for eligibility, the patient’s
consent to participate is obtained in writing and filed in
a confidential research file. Enrolment in this ongoing
study started in September 2012 and will conclude in
September 2016.
Patient screening and consent
Patient screening is performed using a web-based form.
Research staff complete this form for each patient pre-
senting to the ED for evaluation during site research
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staff screening hours (generally 12–16 hours each day).
The web-based screening form prompts the research
assistant (RA) to complete a series of questions. If parti-
cipants are eligible for participation based on these
screening questionnaire responses, then the RA is auto-
matically advanced to the ED assessment interview, and
individuals are approached for study participation. If
individuals are not eligible, the reason for ineligibility
is stored by the system. Signed informed consent is
obtained from all participants.
ED assessment
The ED setting represents a unique opportunity to
collect detailed information from patients shortly after
MVC. The proposed research protocol takes substantially
less time than patients usually spend waiting in the ED
and can generally be completed within this time without
prolonging a patient’s ED stay. ED assessments are con-
ducted by trained RAs using a standardised web-based
questionnaire on laptop computer. Back-up paper
copies are used by RAs if hospital wireless internet
service is unavailable. The ED interview begins with the
collection of patient contact information, including
information on two potential alternative contacts.
Subsequent interview assessments include the collection
of detailed information regarding the collision event,
current and past somatic and psychological symptoms,
expectations of recovery, general health and medication
use (table 1). Participants are compensated $75 for
completing the ED evaluation.
Table 1 Study question domains, specific measures and times of assessment
Domain Measure ED 6WK 6M 1YR
MVC injury events Standardised Questionnaire •
Distress in response to MVC Peritraumatic Distress Inventory50 •
Expectations for recovery Emotional and physical recovery •
Dissociative symptoms in
response to MVC
Michigan Critical Events Perception Scale51 •
Catastrophizing Pain Catastrophizing Scale52 •
Fault and Anger Fault and anger questions relating to MVC •
Pre-MVC pain and somatic
symptoms
Numeric Pain Rating Scale,53 Regional Pain Scale,54 Overall
Pain,55 Somatic Symptom Interview56
•
Pre-MVC general health Short Form-1257 •
Pre-MVC anxiety symptoms State-Trait Anxiety Inventory (Form Y)58 •
Pre-MVC depressive symptoms Center for Epidemiological Studies Depression Scale59 •
Pre-MVC perceived social
support
Multidimensional Scale of Perceived Social Support60 •
Pre-MVC depression anxiety Depression and Anxiety Stress Scale61 •
Experiences of discrimination Major Experience of Discrimination62 •
Ethnic identity Multidimensional Inventory of Black Identity63 •
Demographic information Standard items • • •
Alcohol and drug use TWEAK,64 Substance Abuse Outcomes Module65 • • •
Pre-MVC lifetime trauma
exposure
Traumatic Life Events Questionnaire66 •
Current pain symptoms (neck
and other pains)
Numeric pain Rating Scale,53 Regional Pain Scale,54 Overall
Pain,55 Somatic Symptom Interview56
• • • •
Neuropathic pain DN467 • • • •
Current whiplash Quebec Classification68 • • • •
Fear avoidance Tampa Scale for Kinesiophobia,69 Fear Avoidance Beliefs
Questionnaire70
• • • •
Medication use Standard items • • • •
Discrimination Day to day unfair treatment, Everyday discrimination62 • • • •
Disability/litigation claims Standard items • • • •
Post-MVC depressive and
anxious symptoms
Center for Epidemiological Studies Depression Scale,59
Depression and Anxiety Stress Scale61
• • •
PTSD symptoms Impact of Event Scale-Revised71 • • •
General health Short Form-1257 • • •
New injury or re-injury Standard items • • •
Pain interference Brief Pain Inventory (pain interference questions)72 • • •
Travel anxiety Travel anxiety questions • • •
Missed work or activities Standard items • • •
Health service utilisation Standard items • • •
1YR, 1 year; 6M, 6 months; 6WK, 6 weeks; DN4, neuropathic pain diagnostic questionnaire; ED, emergency department; MVC, motor vehicle
collision; PTSD, post-traumatic stress disorder; TWEAK, alcohol screening instrument for pregnant women.
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ED blood collection
Blood for DNA is collected using a PAXgene DNA
storage tube (8.5 cc). A barcode label is placed on the
tube with a sample number, and a handheld barcode
reader is used to record the sample in the web-based
tracking system and to create a link with the participant’s
study ID number. (The barcode reader is used to
prevent human data entry error.) Each blood sample
number is different from the participant’s study ID
number, to increase confidentiality. DNA blood samples
are then refrigerated at the study site and shipped in
batches every 2 weeks to the UNC Biospecimen
Processing Facility in Chapel Hill, North Carolina, USA.
The barcode is also scanned at the time of shipment
from the study site to the Biospecimen Processing
Facility and at the time of receipt by the Biospecimen
Processing Facility so that blood sample chain of custody
procedures are maintained and sample location can be
continuously monitored.
Blood for RNA are collected using a PAXgene RNA
storage tube (2.5 cc). As with the PAXgene DNA tubes,
PAXgene RNA storage tubes are labelled with a barcode
sample number, which is linked to the participant’s
study ID number using the barcode reader described
above. RNA tubes are frozen immediately at −70°C and
shipped in batches 2–3 times a year to the UNC
Biospecimen Processing Facility. After follow-up informa-
tion is collected, personally identifying information is
stripped from the database so that banked biological
data are de-identified.
Data extraction
Following the participant’s ED visit, RAs at each site
complete a web-based participant data extraction form.
This form collects information from the ED and hospital
medical records related to the study participant’s care,
including the following: ED arrival date and time, par-
ticipant chief symptom, results of any radiologic evalua-
tions, participant injuries by body region (eg, abrasion,
contusion), discharge diagnoses, medications received
in the ED and/or prescribed at discharge, patient
medical history, drug and alcohol screening and ethni-
city of providers. Patient injuries are scored using the
Abbreviated Injury Score (AIS) and Injury Severity Score
(ISS), and the nature of injury (ICD-9-CM codes) and
mechanism of injury (ICD-9 E codes) are recorded.
Medical record data are accessed during the course of
the study to update patient contact information.
Participant follow-up evaluations at 6 weeks, 6 months
and 12 months
At each follow-up evaluation time point, participants
have the choice of completing follow-up evaluations
online, by telephonic interview or by completing paper
versions of the questionnaires and mailing them back to
the study team. Questions are worded so that they can
be completed by any of the above methods. Paper ver-
sions of questionnaires are mailed to all participants at
the beginning of the follow-up window so that those who
wish to complete the survey via telephonic interview can
more easily understand questions and response options.
Individuals who instead wish to complete these paper
forms and mail them in may do so. Participants are com-
pensated $50, $55 and $65 for completing the 6-week,
6-month and 1-year interviews, respectively.
Follow-up assessments include an evaluation of
adverse post-traumatic sequelae such as pain, somatic,
depressive, anger and anxiety symptoms as well as medi-
cation use, pain interference, fear of movement, experi-
ences of discrimination and general health (table 1).
Evaluation of anxiety symptoms at each time point
includes an assessment of PTSD symptoms and travel
anxiety. Missed work, new or re-injury events and litiga-
tion or disability claims are assessed at each follow-up
time point. Demographic information and alcohol,
tobacco and drug use are assessed at the 6- and
12 month time points.
Study hypotheses and primary and secondary analyses
Primary study hypotheses will evaluate whether (1) the
original fear-avoidance model (FAM) of chronic pain
development proposed by Vlaeyen and Linton73 pro-
vides a good fit to the data regarding the pathogenesis
of chronic axial pain after MVC in African-Americans,
(2) past experiences of discrimination influence vulner-
ability to chronic pain after MVC in African-Americans,
(3) ethnic identify modifies any influence by discrimin-
ation and (4) genetic variations in key enzymes and
transporter molecules affecting neuro/stress/immune
system function influence the development of chronic
pain after MVC in African-Americans. In addition to the
above analyses, the rich bounty of data from this first-
ever study of chronic pain development in an
African-American sample will be available for many
other analyses, including analyses evaluating hypotheses
regarding genetic, molecular and epidemiologic factors
influencing chronic pain and other adverse post-MVC
sequelae and analyses evaluating healthcare utilisation
and treatment responses.
Power calculation and proposed statistical analyses
A sister cohort evaluating similar outcomes in European
American individuals following MVC was recently com-
pleted.74 As with that study, the present study was
powered based on proposed genetic analyses, which
require the largest sample size. The previous study, with
n=948, had sufficient power to discover genetic variants
in a number of genes that predicted adverse post-MVC
pain outcomes, including COMT, OPRM1, FKBP5, DRD2
and CRHBP.75–79 As described above, available data indi-
cate that rates of chronic pain development among
African-Americans vs European Americans experiencing
traumatic events such as MVC are substantially
increased. Thus, we anticipate an equal or greater
number of cases in our African-American versus
European American cohort, and sufficient power to
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address our specific aims. Statistical methods used to
evaluate primary and secondary study aims will include
structural equation modelling, latent growth curve
modelling, multivariate regression modelling and
various bioinformatics methods specific to the biological
methods employed.76 78 79
DISCUSSION
As noted above, to date no prospective studies of
chronic pain pathogenesis have been performed in an
African-American population, despite evidence that
African-Americans experience an increased burden of
adverse post-traumatic sequelae such as chronic
post-MVC pain.80 The overarching goal of the present
study is to develop tools that identify individuals at high
risk of adverse sequelae at the time of ED evaluation,
and to develop a better understanding of risk factors
and mediators of chronic pain and neuropsychological
sequelae after MVC so that effective secondary prevent-
ive interventions can be developed.
One aim of the study is to test a well-known cognitive–
behavioural FAM of chronic pain development after
MVC.73 Indirect evidence from cross-sectional and
experimental studies supports the FAM;81–83 however,
the FAM has been assessed only minimally in prospective
cohorts. This study will test the multivariate predictive
relationships in the FAM model in a large prospective
cohort of individuals at increased risk of chronic pain
development.
This cohort study is the sister study to a previously
completed study evaluating adverse post-traumatic seque-
lae, including pain outcomes, in a large cohort of
European Americans (n=948) experiencing MVC.74
Both studies evaluate individuals following the same
trauma/stress exposure (MVC), and use very similar
methods and a very similar battery of assessments to
evaluate individuals across the same follow-up time
points (6 weeks, 6 months and 1 year). In the sister
cohort study, we had a follow-up rate of ≥90% at each of
the three time points. In other studies, follow-up rates
for African-Americans are generally lower than for
European Americans, due to a greater degree of socio-
economic disadvantage in the population. Therefore, we
estimate final loss to follow-up of ∼10–15% at each time
point in the African-American sample.
Several limitations should be noted when interpreting
the results of this study. The first limitation is that we are
using self-report to identify African-American indivi-
duals, which could result in a heterogeneous population.
However, this method of identification is highly valuable
because ethnic identity is not only a biological variable
but also a multidimensional construct encompassing
an individual’s attitudes towards group membership.
Second, the study is limited to patients who come to the
ED after MVC and are discharged to home after evalu-
ation. However, available data indicate that this popula-
tion constitutes more than 90% of MVC patients who
present to the ED for evaluation after MVC.3 Finally,
another limitation is that only about half of the poten-
tially eligible participants are enrolled (based on pilot
data analyses). The generalisability of the results among
individuals who declined enrolment is not known.
However, these limitations are consistent with other
studies enrolling participants after an acute aftermath of
trauma in an ethical manner.
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